Comparing Vildagliptin and Metformin for treating Polycystic Ovary Syndrome
Official title: Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial
Run by October 6 University · NCT06142656 · Data updated 2026-11-12
This study is testing whether Vildagliptin or Metformin works better to help women with Polycystic Ovary Syndrome manage their symptoms.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | October 6 University Academic / other |
| Locations | 1 site (Giza) |
| Status | Recruiting |
| Started | November 25, 2023 |
| Main results expected | December 1, 2025 |
| Study ends | February 1, 2026 |
| Registry record updated | July 30, 2025 |
| Trial ID | NCT06142656 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women diagnosed with PCOS according to established criteria.
✕Probably not a fit
Patients with a history of diabetes mellitus or other specified exclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the efficacy of Vildagliptin compared to Metformin in women diagnosed with Polycystic Ovary Syndrome (PCOS). The study aims to determine which medication is more effective in managing symptoms associated with PCOS, a condition that affects a significant number of women of reproductive age. Participants will be women who meet specific diagnostic criteria for PCOS, and they will receive either Vildagliptin or Metformin as part of the intervention. The trial is designed to assess the outcomes related to symptom relief and overall management of PCOS.
Why it matters
Potential benefit: If successful, this study could provide a more effective pharmacological treatment option for women suffering from PCOS.
How similar studies have gone: While pharmacological treatments for PCOS have been explored, this specific comparison of Vildagliptin and Metformin is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: -Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria. Exclusion Criteria: * Patients with history of diabetes mellitus (Type 1 or 2). * Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months * Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors * Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Where it's running
-
October 6 university hospital
Giza, Egypt Recruiting
Study contacts
- Principal investigator: ahmed hussein, PhD — october 6 university hospital
- Study coordinator: ahmed hussein, phD
- Email: ahmedhussein.med@o6u.edu.eg
- Phone: 01001749605
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if exemestane helps PMOS patients ovulate compared with placebo
This study tests whether daily exemestane can help women with PMOS/PCOS ovulate better than a placebo.
-
Alpha-lipoic acid and myo-inositol for non-diabetic PCOS in women
This trial tests whether adding alpha-lipoic acid to myo-inositol (with or without metformin) helps non-diabetic women with PCOS improve menstrual regularity and ovulation.
-
In vitro maturation of human eggs for fertility treatment
This study is testing a new way to help women with fertility issues by maturing their eggs in the lab with fewer hormones to see if it makes treatment easier and safer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.